The environmental footprint of a membrane bioreactor treatment process through Life Cycle Analysis

This study includes an environmental analysis of a membrane bioreactor (MBR), the objective being to quantitatively define the inventory of the resources consumed and estimate the emissions produced during its construction, operation and end-of-life deconstruction. The environmental analysis was done by the life cycle assessment (LCA) methodology, in order to establish with a broad perspective and in a rigorous and objective way the environmental footprint and the main environmental hotspots of the examined technology. Raw materials, equipment, transportation, energy use, as well as air- and waterborne emissions were quantified using as a functional unit, 1 m3 of urban wastewater. SimaPro 8.0.3.14 was used as the LCA analysis tool, and two impact assessment methods, i.e. IPCC 2013 version 1.00 and ReCiPe version 1.10, were employed. The main environmental hotspots of the MBR pilot unit were identified to be the following: (i) the energy demand, which is by far the most crucial parameter that affects the sustainability of the whole process, and (ii) the material of the membrane units. Overall, the MBR technology was found to be a sustainable solution for urban wastewater treatment, with the construction phase having a minimal environmental impact, compared to the operational phase. Moreover, several alternative scenarios and areas of potential improvement, such as the diversification of the electricity mix and the material of the membrane units, were examined, in order to minimize as much as possible the overall environmental footprint of this MBR system. It was shown that the energy mix can significantly affect the overall sustainability of the MBR pilot unit (i.e. up to 95% reduction of the total greenhouse gas emissions was achieved with the use of an environmentally friendly energy mix), and the contribution of the construction and operational phase to the overall environmental footprint of the system.This work was funded by Nireas, International Water Research Center of the University of Cyprus (ΝΕΑ ΥΠΟΔΟΜΗ/ΣΤΡΑΤΗ/0308/09), which was co-funded by the European Regional Development Fund and the Republic of Cyprus through the Research Promotion Foundation. The authors are grateful to the manufacturer company of the MBR pilot unit, S.K. Euromarket Ltd., as well as to Ms. Popi Karaolia of Nireas-IWRC of the University of Cyprus, for providing technical information to the study

Pharmaceutical pollution of the world's rivers

Environmental exposure to active pharmaceutical ingredients (APIs) can have negative effects on the health of ecosystems and humans. While numerous studies have monitored APIs in rivers, these employ different analytical methods, measure different APIs, and have ignored many of the countries of the world. This makes it difficult to quantify the scale of the problem from a global perspective. Furthermore, comparison of the existing data, generated for different studies/regions/continents, is challenging due to the vast differences between the analytical methodologies employed. Here, we present a global-scale study of API pollution in 258 of the world's rivers, representing the environmental influence of 471.4 million people across 137 geographic regions. Samples were obtained from 1,052 locations in 104 countries (representing all continents and 36 countries not previously studied for API contamination) and analyzed for 61 APIs. Highest cumulative API concentrations were observed in sub-Saharan Africa, south Asia, and South America. The most contaminated sites were in low- to middle-income countries and were associated with areas with poor wastewater and waste management infrastructure and pharmaceutical manufacturing. The most frequently detected APIs were carbamazepine, metformin, and caffeine (a compound also arising from lifestyle use), which were detected at over half of the sites monitored. Concentrations of at least one API at 25.7% of the sampling sites were greater than concentrations considered safe for aquatic organisms, or which are of concern in terms of selection for antimicrobial resistance. Therefore, pharmaceutical pollution poses a global threat to environmental and human health, as well as to delivery of the United Nations Sustainable Development Goals

Solar/TiO2 photocatalytic decomposition of β-blockers atenolol and propranolol in water and wastewater

The photocatalytic conversion of two β-blockers, namely atenolol and propranolol in aqueous TiO2 suspensions was investigated. Irradiation was provided by a solar simulator equipped with 1kW Xe-OP lamp, while emphasis was given on the effect of catalyst type and loading (50-3000mg/L), substrate concentration (5-30mg/L), initial solution pH (3-10), and the addition of H2O2 (0.07-1.4mM) and oxygen on degradation in two matrices (i.e. pure water and treated municipal effluent). Of the various catalysts tested, Degussa P25 was highly active yielding up to about 80% conversion after 120min of reaction. In general, conversion was favored at lower substrate concentrations, near-neutral pH values and in the absence of other organics (i.e. in pure water), while the addition of H2O2 did not accelerate kinetics which seem to follow the Langmuir-Hinshelwood model. Toxicity to D. magna was evaluated prior to and after photocatalytic treatment. Toxicity increased during the early stages of the reaction and then progressively decreased upon the elimination of the substrate and its reaction intermediates, with propranolol being more toxic than atenolol

Pharmaceutical pollution of the world's rivers

Environmental exposure to active pharmaceutical ingredients (APIs) can have negative effects on the health of ecosystems and humans. While numerous studies have monitored APIs in rivers, these employ different analytical methods, measure different APIs, and have ignored many of the countries of the world. This makes it difficult to quantify the scale of the problem from a global perspective. Furthermore, comparison of the existing data, generated for different studies/regions/continents, is challenging due to the vast differences between the analytical methodologies employed. Here, we present a global-scale study of API pollution in 258 of the world's rivers, representing the environmental influence of 471.4 million people across 137 geographic regions. Samples were obtained from 1,052 locations in 104 countries (representing all continents and 36 countries not previously studied for API contamination) and analyzed for 61 APIs. Highest cumulative API concentrations were observed in sub-Saharan Africa, south Asia, and South America. The most contaminated sites were in low- to middle-income countries and were associated with areas with poor wastewater and waste management infrastructure and pharmaceutical manufacturing. The most frequently detected APIs were carbamazepine, metformin, and caffeine (a compound also arising from lifestyle use), which were detected at over half of the sites monitored. Concentrations of at least one API at 25.7% of the sampling sites were greater than concentrations considered safe for aquatic organisms, or which are of concern in terms of selection for antimicrobial resistance. Therefore, pharmaceutical pollution poses a global threat to environmental and human health, as well as to delivery of the United Nations Sustainable Development Goals.N

Pharmaceutical pollution of the world's rivers

Environmental exposure to active pharmaceutical ingredients (APIs) can have negative effects on the health of ecosystems and humans. While numerous studies have monitored APIs in rivers, these employ different analytical methods, measure different APIs, and have ignored many of the countries of the world. This makes it difficult to quantify the scale of the problem from a global perspective. Furthermore, comparison of the existing data, generated for different studies/regions/continents, is challenging due to the vast differences between the analytical methodologies employed. Here, we present a global-scale study of API pollution in 258 of the world's rivers, representing the environmental influence of 471.4 million people across 137 geographic regions. Samples were obtained from 1,052 locations in 104 countries (representing all continents and 36 countries not previously studied for API contamination) and analyzed for 61 APIs. Highest cumulative API concentrations were observed in sub-Saharan Africa, south Asia, and South America. The most contaminated sites were in low- to middle-income countries and were associated with areas with poor wastewater and waste management infrastructure and pharmaceutical manufacturing. The most frequently detected APIs were carbamazepine, metformin, and caffeine (a compound also arising from lifestyle use), which were detected at over half of the sites monitored. Concentrations of at least one API at 25.7% of the sampling sites were greater than concentrations considered safe for aquatic organisms, or which are of concern in terms of selection for antimicrobial resistance. Therefore, pharmaceutical pollution poses a global threat to environmental and human health, as well as to delivery of the United Nations Sustainable Development Goals